Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MEDRx/DWTI Clinch US FDA Approval for Lidocaine Patch
September 26, 2025
- Nippon Zoki Shooting for 50% Overseas Sales by FY2035
September 25, 2025
- Australia Clears Leqembi after Tribunal Review
September 25, 2025
- Taiho Hooks Up with Guardant Health in Biomarker Search
September 25, 2025
- GE HealthCare to Develop Lantheus’ Prostate Cancer PET Agent in Japan
September 25, 2025
- Eisai Settles US Lenvima Suit with Dr. Reddy’s, Generic Launch Barred Until 2030
September 25, 2025
- Enhertu Combo Accepted for US Review in First-Line HER2 Breast Cancer
September 25, 2025
- Chugai Seeks Avastin Label Expansion for Neurofibromatosis Type 2
September 25, 2025
- Mochida and Itochu to Each Take 20% Stake in And Pharma
September 24, 2025
- PharmaEssentia Files for ET Indication of Besremi in Japan
September 24, 2025
- FDA Turns Down Otsuka’s PTSD Bid for Rexulti
September 24, 2025
- Moderna Rolls Out LP.8.1-Tailored Spikevax in Japan
September 24, 2025
- Nikon Bets 10 Billion Yen on Regenerative Medicine CDMO Push
September 22, 2025
- Daiichi Sankyo’s ADC I-DXd Shows Distinct Safety Profile in SCLC: R&D Head
September 22, 2025
- Allergan Seeks Label Expansion for Botox Vista in Japan
September 22, 2025
- Takeda to Ship Medicines via Wind-Powered Vessel from 2026
September 22, 2025
- Nippon Shinyaku’s DMD Med Bags Orphan Status in US
September 22, 2025
- Kisunla Uptake “as Expected” One Year after Approval, Says Lilly Japan Exec
September 19, 2025
- SanBio Eyes Akuugo Label Expansion Talks with PMDA in FY2026
September 19, 2025
- Deciphera’s Romvimza Scores EU Nod as First TGCT Therapy
September 19, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…